Physician profile
Geffrey Klein
NPI 1124020433
$2,594.86
in general payments reported to CMS, 2019-2025
30 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $142 · 2021: $436 · 2022: $522 · 2023: $430 · 2024: $563 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $469.78 | 2019-2022 | |
| Astellas Pharma US INC | $430.84 | 2022-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $282.45 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $142.22 | 2021-2023 | |
| Medtronic, INC. | $140.41 | 2023-2025 | Ligasure, Truclear |
| Lilly USA, LLC | $138.47 | 2024-2025 | Zepbound |
| Novo Nordisk INC | $122.12 | 2024 | Wegovy |
| Lupin INC. | $71.78 | 2019-2021 | |
| Millicent US INC | $68.65 | 2020-2025 | Femlyv, Intrarosa, Femring |
| Organon LLC | $66.79 | 2021-2025 | Nexplanon |
| Evofem Biosciences, INC. | $64.25 | 2021-2023 | Phexxi |
| Aspira Women'S Health INC | $58.15 | 2023-2024 | Ova1 |
| Davol INC. | $57.21 | 2022 | |
| Biogen, INC. | $51.39 | 2024 | Zurzuvae |
| Avion Pharmaceuticals | $49.53 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.70 | 2024-2025 | |
| Hologic Sales and Service, LLC | $40.78 | 2019-2021 | |
| Exeltis, USA INC. | $39.39 | 2021-2022 | |
| Ethicon US, LLC | $34.05 | 2025 | Evarrest |
| Allergan, INC. | $30.57 | 2019-2020 | |
| Covidien LP | $29.93 | 2019 | |
| Therapeuticsmd, INC. | $29.30 | 2019-2020 | |
| Daiichi Sankyo INC. | $22.37 | 2020 | |
| Smith+Nephew, INC. | $19.33 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.21 | 2021 | |
| Mission Pharmacal Company | $16.34 | 2023 | Citranatal |
| Amag Pharmaceuticals, INC. | $15.97 | 2019 | |
| Merck Sharp & Dohme LLC | $15.21 | 2020 | |
| Sage Therapeutics, LLC | $14.65 | 2021 | |
| Ascend Therapeutics US, LLC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geffrey Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.